Literature DB >> 11040002

Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease.

A M Varnava1, P M Elliott, S Sharma, W J McKenna, M J Davies.   

Abstract

OBJECTIVE: To make a quantitative assessment of the relation between disarray, fibrosis, and small vessel disease in hypertrophic cardiomyopathy.
DESIGN: Detailed macroscopic and histological examination at 19 segments of the left and right ventricle and the left atrial free wall. PATIENTS: 72 patients with hypertrophic cardiomyopathy who had suffered sudden death or progression to end stage cardiac failure (resulting in death or heart transplantation). MAIN OUTCOME MEASURES: The presence of scarring, atrial dilatation, and a mitral valve impact lesion were noted, and heart weight, wall thickness, per cent disarray, per cent fibrosis, and per cent small vessel disease quantitated for each heart.
RESULTS: Within an individual heart the magnitude of hypertrophy correlated with the severity of fibrosis (p = 0.006) and disarray (p = 0.0002). Overall, however, total heart weight related weakly but significantly to fibrosis (r = 0.4, p = 0.0001) and small vessel disease (r = 0.3, p = 0.03), but not to disarray. Disarray was greater in hearts with mild left ventricular hypertrophy (maximum wall thickness < 20 mm) and preserved systolic function (60.9 (26)% v 43 (20.4)% respectively, p = 0.02) and hearts without a mitral valve impact lesion (26.3% v 18.9%, p = 0.04), but was uninfluenced by sex. Fibrosis was influenced by sex (7% in male patients and 4% in female, p = 0.04), but not by the presence of an impact lesion. No relation was found between disarray, fibrosis, and small vessel disease.
CONCLUSIONS: Myocyte disarray is probably a direct response to functional or structural abnormalities of the mutated sarcomeric protein, while fibrosis and small vessel disease are secondary phenomena unrelated to disarray, but modified by factors such as left ventricular mass, sex, and perhaps local autocrine factors.

Entities:  

Mesh:

Year:  2000        PMID: 11040002      PMCID: PMC1729476          DOI: 10.1136/heart.84.5.476

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  Asymmetrical hypertrophy of the heart in young adults.

Authors:  D TEARE
Journal:  Br Heart J       Date:  1958-01

2.  Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy.

Authors:  C Yutani; M Imakita; H Ishibashi-Ueda; K Hatanaka; S Nagata; H Sakakibara; Y Nimura
Journal:  Am Heart J       Date:  1985-03       Impact factor: 4.749

3.  Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH). Light and electron microscopic findings.

Authors:  B J Maron; V J Ferrans; W L Henry; C E Clark; D R Redwood; W C Roberts; A G Morrow; S E Epstein
Journal:  Circulation       Date:  1974-09       Impact factor: 29.690

4.  Hypertrophic cardiomyopathy and cardiac muscle cell disorganization revisited: relation between the two and significance.

Authors:  B J Maron; W C Roberts
Journal:  Am Heart J       Date:  1981-07       Impact factor: 4.749

5.  The current status of myocardial disarray in hypertrophic cardiomyopathy.

Authors:  M J Davies
Journal:  Br Heart J       Date:  1984-04

6.  Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis.

Authors:  M G St John Sutton; J T Lie; K R Anderson; P C O'Brien; R L Frye
Journal:  Br Heart J       Date:  1980-10

7.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

8.  Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy.

Authors:  M Tanaka; H Fujiwara; T Onodera; D J Wu; M Matsuda; Y Hamashima; C Kawai
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

9.  Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  F J ten Cate; J Roelandt
Journal:  Am Heart J       Date:  1979-06       Impact factor: 4.749

10.  Morphologic evidence for "small vessel disease" in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  Z Kardiol       Date:  1987
View more
  100 in total

Review 1.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

2.  Sudden death is associated with a widened paced QRS complex in noncoronary cardiac disease.

Authors:  Per Otto Schueller; Marcus Guenter Hennersdorf; Bodo Eckehard Strauer
Journal:  J Interv Card Electrophysiol       Date:  2006-03       Impact factor: 1.900

3.  Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.

Authors:  Paul Knaapen; Willem G van Dockum; Marco J W Götte; Kimiko A Broeze; Joost P A Kuijer; Jaco J M Zwanenburg; J Tim Marcus; Wouter E M Kok; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

4.  Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice.

Authors:  Briar R Ertz-Berger; Huamei He; Candice Dowell; Stephen M Factor; Todd E Haim; Sara Nunez; Steven D Schwartz; Joanne S Ingwall; Jil C Tardiff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-02       Impact factor: 11.205

5.  Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy.

Authors:  Elif Elmas; Christina Doesch; Stephan Fluechter; Miriam Freundt; Christel Weiss; Siegfried Lang; Thorsten Kälsch; Dariush Haghi; Jana Papassotiriou; Jan Kunde; Stefan O Schoenberg; Martin Borggrefe; Theano Papavassiliu
Journal:  Int J Cardiovasc Imaging       Date:  2010-09-26       Impact factor: 2.357

6.  Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy.

Authors:  T Germans; A A M Wilde; C J A van Echteld; O Kamp; Y M Pinto; A C van Rossum
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

Review 7.  T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies.

Authors:  Euler de Vilhena Garcia
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-10       Impact factor: 1.468

Review 8.  Genetics of inherited cardiomyopathy.

Authors:  Daniel Jacoby; William J McKenna
Journal:  Eur Heart J       Date:  2011-08-02       Impact factor: 29.983

9.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

10.  Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study.

Authors:  Deborah H Kwon; Randolph M Setser; Zoran B Popović; Maran Thamilarasan; Srikanth Sola; Paul Schoenhagen; Mario J Garcia; Scott D Flamm; Harry M Lever; Milind Y Desai
Journal:  Int J Cardiovasc Imaging       Date:  2008-01-19       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.